Colony blots and preparation of 32P-labeled probes. After overnight incubation on selective agar plates, E. coli transformants were lifted onto nitrocellulose filters. The colonies were lysed and fixed onto the nitrocellulose by sequential placement of the filters for 5 min each onto Whatman no. 1 filter papers soaked with (i) 1.5 M NaCl-0.5 M NaOH, (ii) 1.5 M NaCl-0.5 M Tris (pH 7.5), (iii) 2x SSC (lx SSC is 0.15 M NaCl plus 0.015 M sodium citrate) (9), and (iv) 70% ethanol.
Group B streptococci (GBS) are a major cause of bacterial sepsis and meningitis in newborn infants (2) . Capsular type III GBS is the predominant serotype isolated from infants with early-onset meningitis or with late infections. The type III capsule is a high-molecular-weight polymer containing galactose, glucose, N-acetylglucosamine, and N-acetylneuraminic acid (sialic acid) moieties. Removal of the terminal side-chain sialic acid from the native form leaves a core polysaccharide that is identical in structure to the capsular polysaccharide of type XIV Streptococcus pneumoniae (18) .
The role of the type III capsular polysaccharide in the virulence of GBS has been demonstrated by Rubens et al. (13) , using Tn916 insertional mutagenesis. Insertion of Tn916 into the chromosome of a type III GBS clinical strain, COH 31rs, generated several isogenic mutants lacking capsular polysaccharide. One of these mutants, COH 31-15, was avirulent when compared with the wild-type strain in a neonatal rat sepsis model.
In COH 31-15, a single Tn916 insertion in a 3.0-kilobase (kb) EcoRI chromosomal fragment ablated capsule expression. This fragment was cloned and, when used as a probe in Southern hybridization analysis, was found to be homologous to a similar-sized fragment in all five GBS serotypes. These data suggested that the genes encoded by this fragment may be part of a common pathway for capsular biosynthesis in all the GBS serotypes.
The importance of the terminal sialic acid side-chain moiety of type III capsular polysaccharide to the virulence of GBS has also been demonstrated by Tn916 mutagenesis of COH 31rs. A single GBS type III mutant, COH , that contained two Tn916 inserts in the chromosome was recently derived. This mutant produced a capsule missing the terminal sialic acid side chain and was also avirulent compared with the wild-type strain (M. R. Wessels et al., submitted for publication). These data confirmed previous reports that suggested that sialylation of the capsular * Corresponding author.
polysaccharide of GBS was an important virulence factor (14) .
The current report describes the mapping of a region of the GBS chromosome involved in type III capsule expression. The locations of the transposon insertion sites in the chromosomes of the COH 31rs capsule mutants are described. The DNA fragments from the capsule gene region have been cloned from a genomic library of a wild-type strain, and the proteins expressed from these fragments have been identified.
MATERIALS AND METHODS
Bacterial strains and plasmids. The bacterial strains used in this study are listed in Table 1, and the plasmids used are  listed in Table 2 .
Cosmid libraries. Genomic cosmid libraries of GBS type III strains were generated by using total cellular DNA from GBS strains isolated by a modification of the procedure of Hull et al. (8) in which 50 ,ug of mutanolysin per ml was used in place of lysozyme. Chromosomal DNA, partially digested with Sau3A, was ligated to BamHI-digested cosmid vector pLH79 (pHC79 cosmid vector [7] with the tet gene removed). Ligation mixtures were packaged in lambda bacteriophage heads in vitro by using the GigaPak packaging kit (Stratagene Cloning Systems, La Jolla, Calif.) After transfection of Escherichia coli DH1, cosmid clones were selected on medium containing 25 ,ug of ampicillin per ml for wild-type libraries and 25 ,ug of ampicillin per ml and 4 pug of tetracycline per ml for mutant libraries to select for clones containing the Tn9J6 transposon.
Colony blots and preparation of 32P-labeled probes. After overnight incubation on selective agar plates, E. coli transformants were lifted onto nitrocellulose filters. The colonies were lysed and fixed onto the nitrocellulose by sequential placement of the filters for 5 min each onto Whatman no. 1 filter papers soaked with (i) 1.5 M NaCl-0.5 M NaOH, (ii) 1.5 M NaCl-0.5 M Tris (pH 7.5), (iii) 2x SSC (lx SSC is 0.15 M NaCl plus 0.015 M sodium citrate) (9) , and (iv) 70% ethanol. The filters were then baked for 30 min at 80°C in a vacuumdrying oven. Fragments of DNA were isolated from agarose gels with Gene Clean (Bio 101, La Jolla, Calif.) and labeled with 32P-deoxynucleotides in vitro by using a random hexanucleotide labeling kit (Pharmacia-LKB Biotechnology, Uppsala, Sweden). Labeled DNA probes were hybridized to the colonies on the filters as described by Maniatis et al. (9) . Cloning and DNA-DNA hybridization. GBS DNA fragments were isolated and subcloned from E. coli cosmid clones by purification of cosmids, electrophoresis of restriction endonuclease-digested cosmids on agarose gels, excision of fragments with Gene Clean, ligation to restriction endonuclease-digested pBS vector DNA (Stratagene Cloning Systems), and transformation into E. coli DH1 (9) . Southern transfer of DNA fragments to nitrocellulose and DNA-DNA hybridization have also been described (9) .
Identification of gene products by maxicell analysis. The E. coli maxicell in vivo system (17) was used to analyze protein products encoded by cloned genes. E. coli cells harboring plasmids that contained GBS DNA fragments were irradiated with UV light and then incubated in the presence of [35S]methionine to label plasmid-encoded proteins. Radiolabeled protein products were resolved by sodium dodecyl Ampr (4.7 kb) This study pCER112 Ampr (3.2 kb) This study sulfate-polyacrylamide gel electrophoresis and visualized by autoradiography.
In vitro coupled transcription-translation system. A modified Zubay method (11) for coupled transcription-translation in a procaryotic cell-free system was used to synthesize proteins from recombinant pBS plasmids containing GBS DNA fragments. The plasmids were incubated with a crude extract from E. coli supplemented with amino acids, an energy-regenerating system, cofactors, and [35S]methionine. Radiolabeled protein products were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and visualized by autoradiography.
RESULTS
Mapping of the type III capsule genes. A genomic cosmid library of COH 1, a virulent type III GBS clinical strain, was generated and used as a source for unmutagenized fragments of GBS chromosomal DNA. COH 1 was chosen for mapping studies because it produces more capsule than COH 31rs and is more virulent in the infant rat model, therefore being more typical of invasive GBS strains isolated from infected infants than is COH 31rs. The 50% lethal dose of COH 1 was 102 CFU/g of animal (10), versus 5 x 105 CFU/g of animal for COH 31rs (13) .
The 3.0-kb EcoRI fragment that flanked the single transposon insertion site in the chromosome of COH 31-15, resulting in an acapsular phenotype, was previously subcloned into E. coli, and the recombinant plasmid was designated pCER3115-1 (13) . The 3.0-kb fragment was labeled with 32P and hybridized to E. coli cosmid clones containing COH 1 DNA. Cosmid DNA from reactive clones was purified and mapped by using restriction endonuclease analysis. GBS DNA fragments from these cosmids were subcloned and used as probes for chromosome-walking studies (1) in Southern hybridizations with restriction endonucleasedigested whole-cell DNA from GBS strains COH 1 and COH 31rs. These studies confirmed the arrangement of the 30-kb putative capsule regions shown in Fig. 1 .
These studies also demonstrated two differences in this genomic region between COH 31rs and COH 1. The first difference was that a restriction fragment length polymorphism was observed ( Fig. 1, asterisk ). An EcoRI site that cut Whole-cell DNA from two wild-type strains and from the seven mutants that contained Tn916 in the 3.0-kb EcoRI fragment was digested with HindIll and analyzed by Southern hybridization analysis, again with the 3.0-kb fragment from COH 31-15 as a probe (Fig. 2B) The transposon appears to have inserted in the same location but in different orientations in these six mutants. In lanes 3, 5, 7, and 9, the probe hybridized to a 7.2-kb fragment containing the smaller piece of Tn9O6, and in lanes 6 and 8, the probe hybridized to an 18.1-kb fragment containing the larger piece of Tn916. In one mutant, COH 31-6, the 3.0-kb EcoRI fragment hybridized to the 2.2-kb HindIII fragment and to a 6.3-kb HindlIl fragment (lane 4). Therefore, Tn916 inserted into the 1.2-kb HindIII fragment that overlaps the right-hand side of the 3.0-kb EcoRI fragment (Fig. 1) .
To determine the sites of the Tn916 insertions in the desialylated mutant, COH 31-21, we generated a genomic cosmid library. Cosmid clones were selected on medium containing ampicillin and tetracycline to isolate cosmids with GBS DNA containing the transposon. Tn916 is unstable in E. coli and will excise and segregate unless the strain is maintained on tetracycline-containing medium (5) . The DNA flanking the transposon in each cosmid containing Tn916 was obtained by growing the clones with and without tetracycline. Figure 3 shows the EcoRI digests of plasmid DNA from a tetracycline-resistant COH 31-21 cosmid clone grown with (lane C) and without (lane D) tetracycline. The arrow designates the 7.5-kb EcoRI fragment that flanked Tn916. COH 31-21 contained two Tn916 inserts in the chromosome. A 1.0-kb EcoRI fragment flanked theother Tn916 insertion site (data not shown). The two EcoRI fragments that flanked each of the two transposon insertions were purified from agarose and subcloned into the EcoRI site of the pBS vector. The recombinant plasmids, designated pCER212-1 (containing the 1.0-kb fragment) and pCER3121-1 (containing the 7.5-kb fragment), were used for restriction endonuclease mapping and DNA probes.
The Tn916 insertion site in the 7.5-kb EcoRI fragment of COH 31-21 mapped only 10.5 kb to the left of the transposon insertion site in COH 31-15 (Fig. 1) . The 1.0-kb flanking DNA from the second Tn916 insertion site in COH 31-21 was not located within the mapped region. experiments against EcoRI-digested whole-cell DNA from the other GBS types. In a previous study (13) , the 3.0-kb EcoRI fragment from COH 31-15 hybridized to a similarsized EcoRI fragment in chromosomal DNA from GBS serotypesIa, Tb, Ic, andII. The 9.0-, 3.65-, and 1.4-kb EcoRI fragments and the 2.5-kb EcoRI-HindITI fragment from COH 1 (Fig. 1) were used as probes against the same blot containing EcoRI-digested whole-cell DNA from three other types III GBS and from serotypes II, Ta, Ib, and Ic. The results are shown in Fig. 4 .
Like the 3.0-kb EcoRI fragment, the 3.65-and 1.4-kb EcoRI fragments hybridized to similar-sized fragments, respectively, in chromosomal DNA from the eight GBS tested (Fig. 4A and B) . However, the 9.0-kb EcoRI fragment from COH 1 hybridized to 7.5-and 1.5-kb fragments in COH 31rs (Fig. 4C, lane d) . As mentioned above, a restriction fragment length polymorphism was observed between COH 31rs and COH 1 in that region. Hybridization of the 9.0-kb fragment to DNA from the other two type III GBS and to the type II andIb isolates resulted in a similar-sized fragment as the probe (9.0 kb), whereas serotypes Ic and Ia yielded fragments similar in size to those in COH 31rs (7.5 and 1.5 kb).
The 2.5-kb EcoRI-HindIII fragment from COH 1 was a subclone of the larger (4.6-kb) EcoRI fragment. When the 2.5-kb EcoRI-HindIII fragment was used as a probe against EcoRI-digested whole-cell DNA from COH 1, it hybridized to the 4.6-kb EcoRI fragment and to eight other fragments (Fig. 4D, lane a) . The same pattern of nine fragments was observed when the probe was hybrized to EcoRI-digested whole-cell DNA from M732, another type III GBS (Fig. 4B,  lane [35S] methionine. The proteins made from each set of maxicells were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and the gels were autoradiographed (Fig. 5) . DH1 alone did not synthesize any plasmid-encoded proteins, and background expression of chromosomal DNA was not observed (Fig. 5A and B, lanes  1) . The vector encoded a ,B-lactamase of 29 kilodaltons (kDa) and occasionally a small amount of the larger precursor P-lactamase (31 kDa) (Fig. SA and B, lanes 2) . Plasmids containing GBS inserts produced proteins in addition to P-lactamase. Figure 6 shows EcoRI-Aval fragment within it expressed similar-sized proteins. Figure SA , lane 3, shows the 40-, 38-, and 34-kDa proteins produced by maxicell clones containing the 3.3-kb EcoRI-AvaI fragment (pCER109). The 9.0-kb fragment expressed the same 38-and 34-kDa proteins and also a 43-kDa protein instead of the 40-kDa protein produced by the 3.3-kb fragment. This smaller, 40-kDa protein may be a truncated form of the larger, 43-kDa protein whose gene spans the AvaI restriction endonuclease site. The maxicell clone with the 3.65-kb EcoRI fragment (pCER108) produced 31-, 23-, 18-, and 16-kDa proteins (Fig.  SA, lane 4) . The 3.0-kb insert (pCER107) produced 27-, 24-, and 22-kDa proteins (Fig. 5A, lane 5) . The 3.5-kb XbaI fragment was a subclone (pCER106) that straddled the center of the adjacent 3.65-and 3.0-kb EcoRI fragments (Fig.  SA, lane 6 ). This fragment produced two proteins (18 and 16 kDa) that comigrated with proteins produced by the 3.65-kb fragment, one protein (22 kDa) that comigrated with a protein produced by the 3.0-kb fragment, and one unique protein (25 kDa) that may be a partial protein corresponding to the 31-kDa protein from the 3.65-kb fragment or the 27-kDa protein from the 3.0-kb fragment. The locations within the cloned fragments of the genes encoding these proteins have yet to be determined.
Several subclones from the 4.6-kb EcoRI segment of the chromosome were analyzed (Fig. SB) . Four proteins of 36-, (Fig. SB, lanes 3 and 4) . Some of the plasmids with GBS DNA fragments were tested in an in vitro transcription-translation expression system to confirm the results from the maxicell experiments. This system was also used to identify plasmid-encoded proteins that may be secreted. These proteins are synthsized with a signal peptide that is cleaved in maxicells when the protein is secreted but remains intact in the in vitro assays. Proteins expressed by both methods were separated on the same polyacrylamide gel, and the molecular masses were compared. The apparent mass of a secreted protein will be 1 or 2 kDa larger in the in vitro system than in the maxicell assay. In the in vitro transcription-translation assay, the pBS vector expressed a 31-kDa protein that was the precursor form of the P-lactamase. (4, 15, 16) . In addition, some of the Kl capsule genes share significant DNA homology with genes involved in the production of other K-type capsules in E. coli (12) .
We have identified some of the genes that code for GBS type III capsule biosynthesis by using the technique of Tn9J6 mutagenesis. Two distinct phenotypes of capsular mutants were isolated. One class of mutant expressed no capsular material that reacted with native or core antibody (anti-type XIV S. pneumoniae (13) . The other class of mutant bound antibody to core antigen only (Wessels et al., submitted) and was shown to produce only the desialylated form of the capsule. Therefore, the defect in this mutant occurs in the metabolic pathway for sialic acid or in the process which adds sialic acid to the capsular polysaccharide. We have localized the sites of the Tn9J6 insertions that resulted in the altered capsular phenotypes to a 30-kb section of the GBS chromosome. However, for two of the nine acapsular mutants, the transposon site responsible for the mutation did not fall within this 30-kb section. In addition, only one of the two transposon insertion sites for the desialylated mutant was mapped to this region. These data suggest a regional location on the GBS chromsome for some of the genes necessary for type III capsular biosynthesis. They also show that some type III capsule genes may be located elsewhere in the GBS chromosome.
The region of the GBS chromosome responsible for type III capsular biosynthesis was mapped in two type III isolates. Strain COH 1 was isolated from an infant with sepsis and meningitis. Strain COH 31rs was isolated from a leg ulcer of an adult and is poorly encapsulated and less virulent than COH 1. The amount of capsular polysaccharide produced is important for virulence (13) (6) . In addition, pneumococcal DNA fragments cloned into E. coli exhibited strong promoter activity (3) .
Because the 7.5-and 3.0-kb EcoRI fragments were interrupted by Tn916 in COH 31-21 and 31-15, respectively, the protein products encoded by the genes within those fragments are particularly interesting. Some of the proteins expressed by those regions may be secreted proteins that function outside the cytoplasmic membrane. For example, the desialylated phenotype of COH 31-21 may be due to a mutation of a sialyltransferase that catalyzes the incorporation of sialic acid into the core polysaccharide. Secreted proteins are synthesized as precursor forms with signal peptides that are cleaved when secreted, and maxicells most often demonstrate the cleaved product (16) . An in vitro coupled transcription-translation expression system was used to identify plasmid-encoded proteins that retained a signal peptide, inferred by a higher molecular mass in this system than in the maxicell system (11) . Three of the proteins expressed by the capsule genes flanking the transposon insertions in the 7.5-and 3.0-kb EcoRI fragments appeared to be larger when synthesized in vitro than when synthesized by maxicells and are possibly secreted proteins. We are currently undertaking further characterization of the proteins expressed by the genes in both of these regions.
We have begun to identify the genes and their products responsible for type III capsular biosynthesis. We believe that other genes that have not yet been identified are also necessary for type III capsule production. Isolation and characterization of the type III capsule genes will enable us to learn more about the molecular and genetic events controlling capsule synthesis, transport, and secretion.
